Adalimumab Produkte
(Adalimumab)
Kategorien
antibodies-online.com steht für hochwertige Forschungsprodukte. Suchen, finden und bestellen Sie Tools mit umfangreichen Validierungsdaten, Bildern, Referenzen. Unser wissenschaftlicher Kundenservice steht Ihnen jederzeit zur Verfügung, wenn Sie Fragen zur Auswahl oder Anwendung unserer Produkte haben.
Empfohlene Adalimumab Antikörper
Produkt
Reaktivität
Applikation
Validierungen
Kat. Nr.
Menge
Datenblatt
Reaktivität
Human
Applikation
ELISA, IGA
Validierungen
Kat. Nr.
ABIN7515206
Menge
40 μg
Datenblatt
Datenblatt
Empfohlene Adalimumab ELISA Kits
Produkt
Reaktivität
Analytical Method
Validierungen
Kat. Nr.
Menge
Datenblatt
Reaktivität
Chemical, Human
Analytical Method
Quantitative Sandwich ELISA
Validierungen
- (1)
Kat. Nr.
ABIN2862650
Menge
96 tests
Datenblatt
Datenblatt
Reaktivität
Human, Mouse, Rat
Analytical Method
Quantitative Sandwich ELISA
Validierungen
Kat. Nr.
ABIN4886389
Menge
96 tests
Datenblatt
Datenblatt
Neueste Publikationen zu unseren Adalimumab Produkten
: "Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease." in: Journal of gastroenterology and hepatology, Vol. 33, Issue 3, pp. 631-637, (2018) (PubMed).: "IL26 modulates cytokine response and anti-TNF consumption in Crohn's disease patients with bacterial DNA." in: Journal of molecular medicine (Berlin, Germany), Vol. 95, Issue 11, pp. 1227-1236, (2018) (PubMed).
: "Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease." in: Alimentary pharmacology & therapeutics, Vol. 45, Issue 8, pp. 1135-1145, (2017) (PubMed).
: "Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis." in: PLoS ONE, Vol. 11, Issue 12, pp. e0167757, (2017) (PubMed).
: "Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study." in: Pediatric gastroenterology, hepatology & nutrition, Vol. 19, Issue 2, pp. 116-22, (2016) (PubMed).
: "Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation." in: Scandinavian journal of gastroenterology, Vol. 51, Issue 2, pp. 196-202, (2016) (PubMed).
: "Adalimumab trough levels and response to biological treatment in patients with inflammatory bowel disease: a useful cutoff in clinical practice." in: The American journal of gastroenterology, Vol. 110, Issue 3, pp. 472-3, (2015) (PubMed).
: "Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease." in: Journal of gastroenterology, Vol. 50, Issue 7, pp. 758-68, (2015) (PubMed).
: "Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease." in: Gut, Vol. 63, Issue 2, pp. 272-80, (2014) (PubMed).
: "Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children." in: Inflammatory bowel diseases, Vol. 20, Issue 3, pp. 495-501, (2014) (PubMed).
Haben Sie etwas anderes gesucht?
Sie sind hier:
